• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    Peripheral Artery Disease Market Research Report - Forecast till 2032 Infographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Peripheral artery disease Market

    ID: MRFR/MED/1011-CR
    137 Pages
    Kinjoll Dey
    February 2020

    Peripheral Artery Disease Market Research Report Information By Treatment Type (Device, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Others), By Drugs (Lipid Lowering Drugs, Triple-H Therapy, Glucose Regulating Drugs, Blood Clot Preventing Drugs, Inotropes, Thrombolytic Agents, and Anti-Inflammatory Agents), By End User (Hospitals & Clinics, and Ambulatory Surgical Clinics) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Peripheral Artery Disease Market Research Report - Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Peripheral artery disease Market Summary

    As per Market Research Future Analysis, the Global Peripheral Artery Disease Market was valued at USD 2.69 Billion in 2023 and is projected to grow to USD 4.91 Billion by 2032, with a CAGR of 6.80% from 2024 to 2032. Key drivers include the rising demand for minimally invasive procedures and an increasing elderly population. The market is significantly influenced by the prevalence of peripheral artery disease (PAD), which affects over 200 million individuals globally. The North American region is expected to dominate the market due to high cardiovascular disease rates and a strong presence of industry players.

    Key Market Trends & Highlights

    The market is witnessing several trends that are shaping its growth trajectory.

    • The demand for minimally invasive procedures is driving market growth.
    • The hemodynamic flow alteration devices segment dominated the market.
    • The hospitals & clinics segment generated the most revenue among end users.
    • The Asia-Pacific region is expected to grow at the fastest CAGR from 2023 to 2032.

    Market Size & Forecast

    2023 Market Size USD 2.69 Billion
    2024 Market Size USD 2.899 Billion
    2032 Market Size USD 4.91 Billion
    CAGR (2024-2032) 6.80%

    Major Players

    Key players include Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, and Cardinal Health.

    Peripheral artery disease Market Trends

    Rise in demand for minimally invasive procedures is driving the market growth

    Market CAGR for peripheral artery disease is being driven by the rising demand for minimally procedures. Growing demand for less invasive procedures and an uptick in peripheral arterial disease (PAD) cases are negatively impacting the market's expansion. Peripheral artery disease (PAD), which affects more than 200 million individuals worldwide and is linked to high mortality and morbidity, is described in the American Heart Association's 2021 report. The ageing of the world's population will probably lead to an increase in PAD cases in the future.

    Thus, as per the statistics, the number of PAD is growing more quickly, which ultimately is pushing the market for peripheral vascular devices.

    Lower extremity peripheral artery disease (PAD) affects more than 230 million people worldwide and is associated with rising risk of a count of unfavorable clinical outcomes, including cardiovascular diseases like coronary heart disease and stroke and limb outcomes, as per a study published by American Heart Association in August 2021 and titled "Lower Extremity Peripheral Artery Disease Contemporary Epidemiology, Management Gaps, and Future Directions." Over the projected period, the market for peripheral vascular devices would benefit from the rising prevalence of PAD.

    Other than COVID-19, which had a substantial impact on market, the COVID-19 pandemic had a detrimental impact on treatment and diagnostic methods. It also had a negative impact on research and development activities in the sector. The fact that many studies indicated that persons with heart illnesses were particularly vulnerable to COVID-19 also contributed to the decline in patient traffic to hospitals and diagnostic facilities.

    For instance, the National Centre for Biotechnology Information reported that during the COVID-19 pandemic, cardiac procedural activity in England drastically decreased, with a deficit of about 45,000 procedures, with no increase in the risk of mortality for the majority of cardiac procedures performed during the pandemic. This finding has been supported by a research titled "Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality," which was published by the National Centre for Biotechnology Information in May 2021. This study demonstrates how COVID-19 has a detrimental effect on cardiology services.

    The investigation was also carried out in England. The investigation was also carried out in England. Thus, driving the Peripheral Artery Disease market revenue.

    The increasing prevalence of risk factors such as diabetes and hypertension is likely to drive the demand for innovative treatment options in the Peripheral Artery Disease market.

    Centers for Disease Control and Prevention (CDC)

    Peripheral artery disease Market Drivers

    Rising Prevalence of Peripheral Artery Disease

    The increasing prevalence of Peripheral Artery Disease (PAD) is a primary driver for the Global Peripheral Artery Disease Market Industry. As populations age, the incidence of PAD is expected to rise, particularly among individuals over 50 years. In 2024, the market is projected to reach 2.9 USD Billion, reflecting the growing need for effective treatment options. Factors such as diabetes, hypertension, and smoking contribute to this trend, leading to a higher demand for diagnostic and therapeutic solutions. The Global Peripheral Artery Disease Market Industry must adapt to these changing demographics to meet the needs of an expanding patient population.

    Market Segment Insights

    Peripheral Artery Disease Type Insights

    The Peripheral Artery Disease market segmentation, based on type includes Device, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Others. The hemodynamic flow alteration devices segment dominated the market. Peripheral vascular illnesses, which are brought on by the growth of atherosclerotic plaques in the arteries that supply blood to numerous organs, the head, and the limbs, are treated with hemodynamic flow alteration devices.

    Peripheral Artery Disease Drugs Insights

    The Peripheral Artery Disease market segmentation is based on drugs, Lipid-Lowering Drugs, Triple-H Therapy, Glucose Regulating Drugs, Blood Clot Preventing Drugs, Inotropes, Thrombolytic Agents, and Anti-Inflammatory Agents. The triple-H therapy category generated the most income. After aneurysmal subarachnoid haemorrhage (SAH), cerebral vasospasm is frequently prevented and treated using induced hypertension, hypervolemia, and hemodilution (triple-H therapy). The effectiveness of triple-H therapy and its precise function in the management of the acute phase of SAH are still unknown, despite the fact that this paradigm has received universal support over the past 20 years.

    Peripheral Artery Disease End User Insights

    The Peripheral Artery Disease market segmentation is based on end user, includes Hospitals & Clinics, and Ambulatory surgical clinics. The hospitals & clinics category generated the most income. The segmental growth is anticipated to be boosted by rising healthcare capital equipment expenditures, the favorable influence of technology utilizing lifeline curves, and innovations in healthcare regulatory scenarios.

    Figure 1 Peripheral Artery Disease Market, by End User, 2023 & 2032 (USD Billion)

    Source Secondary Research, Primary Research, MRFR Database and Analyst Review

    Get more detailed insights about Peripheral Artery Disease Market Research Report - Forecast till 2032

    Request Free Sample

    Regional Insights

    By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Peripheral Artery Disease market area will dominate this market, owing to an increase in the instances of cardiovascular diseases. In addition, the solid presence of industry players will boost market growth in this region.

    Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2 PERIPHERAL ARTERY DISEASE MARKET SHARE BY REGION 2023 (USD Billion)PERIPHERAL ARTERY DISEASE MARKET SHARE BY REGION 2022

    Source Secondary Research, Primary Research, MRFR Database and Analyst Review

    Europe Peripheral Artery Disease market accounts for the second-largest market share due to the rising smoking, and obesity among the population within the region. Further, the German Peripheral Artery Disease market held the largest market share, and the UK Peripheral Artery Disease market was the fastest growing market in the European region

    The Asia-Pacific Peripheral Artery Disease Market is expected to grow at the quickest CAGR from the period of 2023 to 2032. This is due to growing healthcare expenditures and growing geriatric population. Moreover, China’s Peripheral Artery Disease market held the largest market share, and the Indian Peripheral Artery Disease market was the fastest growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are undergoing various innovations activity to diversify their product & service offerings, which will help the Peripheral Artery Disease market, grow even more. Market participants are undertaking various strategic tactics to grow their presence, with key market developments including new product innovations, contracts & agreements, mergers & acquisitions, higher investments, partnerships, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Peripheral Artery Disease industry must offer cost-effective items.

    The producers are utilizing locally available raw materials to stand in the competition in the Peripheral Artery Disease industry to benefit clients and increase the market sector. In recent years, the Peripheral Artery Disease industry has offered some of the most significant advantages to medicine. Major players in the Peripheral Artery Disease market, including Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik Cardinal Health., and others, are attempting to increase market demand by investing in research and development operations.

    Becton Dickinson and Co. (BD) is a manufacturer and distributor of medical equipment, reagents, and instruments is. Syringes and pen needles, intravenous catheters, infusion pumps, disposables, automated medication dispensing and supply management systems, pre-fillable drug delivery systems, respiratory ventilation and diagnostic equipment and consumables, items for the secure collection and transportation of diagnostic specimens, instruments and reagent systems to detect a variety of infectious diseases and cancers, and clinical research tools are among its main products.

    Researchers who are working in the branch of life sciences, hospitals, clinics, the pharmaceutical sector, and the general public can all benefit from BD's products. In August 2022, The first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB) has begun, according to BD (Becton, Dickinson and business) (NYSE BDX), a top  medical technology business.

    Koninklijke Philips NV (Philips) is a diversified technology firm that creates and produces consumer electronics and medical solutions. Diagnostic imaging, enterprise diagnostic informatics, image-guided therapy, ultrasound, monitoring and analytics, sleep and respiratory care, population health management, linked care informatics, and therapeutic care are all sectors in which the business provides products and solutions. Products available include power toothbrushes, brush heads, baby bottles, sterilisers, breast pumps, shavers, groomers, trimmers, and items for skin, hair, and hair removal. It also sells personal care and dental healthcare items.

    In August 2020, A deal to acquire Intact Vascular, Inc., a company based in the United States that creates medical equipment for minimally invasive peripheral vascular operations, was announced by Royal Philips.

    Key Companies in the Peripheral artery disease Market market include

    Industry Developments

    • Q2 2024: LimFlow Announces FDA Approval of LimFlow System for Treatment of Chronic Limb-Threatening Ischemia (CLTI) LimFlow received FDA premarket approval for its LimFlow System, a minimally invasive device designed to treat patients with chronic limb-threatening ischemia, a severe form of peripheral artery disease.
    • Q2 2024: CardioFlow Receives CE Mark Approval for Peripheral Artery Disease Device CardioFlow announced it has received CE Mark approval for its new peripheral artery disease treatment device, enabling commercialization in the European Union.
    • Q2 2024: PQ Bypass Announces First Commercial Use of DETOUR System Following FDA Approval PQ Bypass reported the first commercial use of its DETOUR System for treating long femoropopliteal lesions in peripheral artery disease patients, following recent FDA approval.
    • Q3 2024: Shockwave Medical Announces FDA Clearance of Shockwave M5+ Peripheral IVL Catheter Shockwave Medical received FDA clearance for its M5+ Peripheral Intravascular Lithotripsy (IVL) Catheter, expanding its portfolio for treating peripheral artery disease.
    • Q3 2024: Boston Scientific Completes Acquisition of Silk Road Medical Boston Scientific completed its acquisition of Silk Road Medical, a company specializing in devices for the treatment of vascular diseases including peripheral artery disease.
    • Q3 2024: Inari Medical Announces FDA Clearance for ClotTriever BOLD Catheter for Peripheral Thrombectomy Inari Medical received FDA clearance for its ClotTriever BOLD catheter, designed for the removal of blood clots in patients with peripheral artery disease.
    • Q4 2024: BD Launches New Peripheral Artery Disease Balloon Catheter in the U.S. BD (Becton, Dickinson and Company) launched a new balloon catheter for the treatment of peripheral artery disease in the United States.
    • Q4 2024: Medtronic Announces FDA Approval of IN.PACT AV Drug-Coated Balloon for Peripheral Artery Disease Medtronic received FDA approval for its IN.PACT AV drug-coated balloon, expanding its portfolio of devices for the treatment of peripheral artery disease.
    • Q1 2025: Penumbra Announces European Launch of Indigo Aspiration System for Peripheral Artery Disease Penumbra launched its Indigo Aspiration System in Europe, designed for the removal of thrombus in patients with peripheral artery disease.
    • Q1 2025: Abbott Receives FDA Approval for New Peripheral Stent System Abbott received FDA approval for its new peripheral stent system, intended to treat patients with peripheral artery disease.
    • Q2 2025: Philips Launches New Image-Guided Therapy System for Peripheral Artery Disease Philips launched a new image-guided therapy system designed to improve the diagnosis and treatment of peripheral artery disease.
    • Q2 2025: Surmodics Announces FDA Approval of SurVeil Drug-Coated Balloon for Peripheral Artery Disease Surmodics received FDA approval for its SurVeil drug-coated balloon, a device for the treatment of peripheral artery disease.

    Future Outlook

    Peripheral artery disease Market Future Outlook

    The Global Peripheral Artery Disease Market is projected to grow at a 6.8% CAGR from 2024 to 2035, driven by increasing prevalence, technological advancements, and rising awareness.

    New opportunities lie in:

    • Develop innovative minimally invasive treatment options to enhance patient outcomes.
    • Leverage telehealth solutions for remote monitoring and management of PAD patients.
    • Invest in targeted marketing campaigns to raise awareness and drive early diagnosis.

    By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased patient engagement.

    Market Segmentation

    Peripheral Artery Disease Drugs Outlook

    • Lipid Lowering Drugs
    • Triple-H Therapy
    • Glucose Regulating Drugs
    • Blood Clot Preventing Drugs,
    • Inotropes,
    • Thrombolytic Agents,
    • Anti-Inflammatory Agents

    Peripheral Artery Disease End User Outlook

    • Hospitals & Clinics
    • Ambulatory Surgical Clinics

    Peripheral Artery Disease Regional Outlook

    North America
    • US
    • Canada

    Peripheral Artery Disease Treatment Type Outlook

    • Device
    • Catheters
    • Plaque Modification Devices
    • Hemodynamic Flow Alteration Devices
    • Others

    Report Scope

    Peripheral Artery Disease Report Scope

    Attribute/Metric Details
    Market Size 2023 USD 2.69 Billion
    Market Size 2024 USD 2.899 Billion
    Market Size 2032 USD 4.91 Billion
    Compound Annual Growth Rate (CAGR) 6.80% (2024-2032)
    Base Year 2023
    Market Forecast Period 2023-2032
    Historical Data 2018- 2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Treatment Type, Drugs, End User, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation
    Key Market Opportunities Growing obesity and elderly population
    Key Market Dynamics Increase in healthcare expenditures and rising consumer spending over health and fitness

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Get In Touch
    Leave a Comment

    FAQs

    How much is the Peripheral Artery Disease market?

    The Peripheral Artery Disease market size was valued at USD 2.69 Billion in 2023.

    What is the growth rate of the Peripheral Artery Disease market?

    The market is projected to grow at a CAGR of 6.80% during the forecast period, 2024-2032.

    Which region held the largest market share in the Peripheral Artery Disease market?

    North America had the largest share in the market

    Who are the key players in the Peripheral Artery Disease market?

    The key players in the market are Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation.

    Which treatment type led the Peripheral Artery Disease market?

    The Catheters category dominated the market in 2022.

    Which end user had the largest market share in the Peripheral Artery Disease market?

    The hospitals & clinics had the largest share in the  market.

    1. EXECUTIVE SUMMARY
      1. OVERVIEW 15
        1. MARKET SYNOPSIS
    2. MARKET INTRODUCTION
      1. SCOPE OF THE STUDY 16
      2. RESEARCH OBJECTIVE 16
      3. LIST OF ASSUMPTIONS 16
    3. RESEARCH
    4. METHODOLOGY
      1. OVERVIEW 18
      2. DATA MINING 18
      3. SECONDARY RESEARCH 19
      4. PRIMARY RESEARCH 20
    5. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 20
      1. BREAKDOWN
    6. OF PRIMARY RESPONDENTS 21
      1. FORECASTING TECHNIQUES 21
    7. RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
      1. BOTTOM-UP APPROACH
        1. TOP-DOWN APPROACH 24
      2. DATA TRIANGULATION 24
      3. VALIDATION 24
    8. MARKET DYNAMICS
      1. OVERVIEW 25
      2. DRIVERS 26
        1. RISING GERIATRIC POPULATION AND SUBSEQUENT
    9. INCREASE IN THE PREVALENCE OF
    10. PERIPHERAL ARTERY DISEASES 26
      1. PRODUCT LAUNCH AND TECHNOLOGICAL ADVANCEMENT 26
        1. INCREASING
    11. CASES OF DIABETES 27
      1. DRIVERS IMPACT ANALYSIS 27
    12. RESTRAINTS 28
      1. PRODUCT RECALLS 28
        1. RESTRAINTS IMPACT
    13. ANALYSIS 28
      1. OPPORTUNITIES 28
        1. ENTRY OF MARKET PLAYERS
    14. INTO EMERGING ECONOMIES 28
    15. MARKET FACTOR ANALYSIS
      1. PORTER’S
    16. FIVE FORCES MODEL 29
      1. THREAT OF NEW ENTRANTS 30
    17. BARGAINING POWER OF SUPPLIERS 30
      1. THREAT OF SUBSTITUTES 30
        1. BARGAINING POWER OF BUYERS 30
        2. INTENSITY OF RIVALRY 30
      2. VALUE CHAIN ANALYSIS 31
        1. R&D AND DESIGNING 32
        2. MANUFACTURING 32
        3. DISTRIBUTION 32
    18. MARKETING & SALES 32
      1. POST-SALES MONITORING 32
    19. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
      1. OVERVIEW 33
      2. DEVICES 34
        1. ANGIOPLASTY BALLOON 36
    20. ANGIOPLASTY STENTS (STENTING) 37
      1. CATHETERS 37
    21. PLAQUE MODIFICATION DEVICES (ATHERECTOMY) 38
      1. HEMODYNAMIC FLOW ALTERATION
    22. DEVICES 38
      1. DRUGS 39
        1. LIPID-LOWERING DRUGS 40
        2. BLOOD PRESSURE LOWERING DRUGS 41
        3. GLUCOSE REGULATING DRUGS
        4. BLOOD CLOT PREVENTING DRUGS 42
    23. PERIPHERAL ARTERY
    24. DISEASE MARKET, BY END USER
      1. OVERVIEW 43
        1. HOSPITALS
    25. AND CLINICS 45
      1. AMBULATORY SURGERY CENTERS 45
    26. GLOBAL
    27. PERIPHERAL ARTERY DISEASE MARKET, BY REGION
      1. OVERVIEW 46
      2. AMERICAS 47
    28. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    29. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. NORTH AMERICA
    30. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    31. PERIPHERAL
    32. ARTERY DISEASE MARKET, BY END USER
      1. US 53
    33. PERIPHERAL
    34. ARTERY DISEASE MARKET, BY TREATMENT TYPE
    35. PERIPHERAL ARTERY DISEASE MARKET,
    36. BY END USER
      1. CANADA 55
    37. PERIPHERAL ARTERY DISEASE MARKET,
    38. BY TREATMENT TYPE
    39. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. LATIN AMERICA 57
    40. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT
    41. TYPE
    42. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. EUROPE
    43. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    44. PERIPHERAL
    45. ARTERY DISEASE MARKET, BY END USER
      1. WESTERN EUROPE 62
    46. PERIPHERAL
    47. ARTERY DISEASE MARKET, BY TREATMENT TYPE
    48. PERIPHERAL ARTERY DISEASE MARKET,
    49. BY END USER
      1. GERMANY 66
    50. PERIPHERAL ARTERY DISEASE MARKET,
    51. BY TREATMENT TYPE
    52. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. FRANCE 68
    53. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    54. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. UK 70
    55. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    56. PERIPHERAL
    57. ARTERY DISEASE MARKET, BY END USER
      1. ITALY 72
    58. PERIPHERAL
    59. ARTERY DISEASE MARKET, BY TREATMENT TYPE
    60. PERIPHERAL ARTERY DISEASE MARKET,
    61. BY END USER
      1. SPAIN 74
    62. PERIPHERAL ARTERY DISEASE MARKET,
    63. BY TREATMENT TYPE
    64. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. REST OF WESTERN EUROPE 76
    65. PERIPHERAL ARTERY DISEASE MARKET,
    66. BY TREATMENT TYPE
    67. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. EASTERN EUROPE 78
    68. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT
    69. TYPE
    70. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. ASIA-PACIFIC
    71. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    72. PERIPHERAL
    73. ARTERY DISEASE MARKET, BY END USER
      1. CHINA 83
    74. PERIPHERAL
    75. ARTERY DISEASE MARKET, BY TREATMENT TYPE
    76. PERIPHERAL ARTERY DISEASE MARKET,
    77. BY END USER
      1. JAPAN 85
    78. PERIPHERAL ARTERY DISEASE MARKET,
    79. BY TREATMENT TYPE
    80. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. INDIA 87
    81. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    82. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. AUSTRALIA
    83. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    84. PERIPHERAL
    85. ARTERY DISEASE MARKET, BY END USER
      1. SOUTH KOREA 91
    86. PERIPHERAL
    87. ARTERY DISEASE MARKET, BY TREATMENT TYPE
    88. PERIPHERAL ARTERY DISEASE MARKET,
    89. BY END USER
      1. REST OF ASIA-PACIFIC 93
    90. PERIPHERAL ARTERY
    91. DISEASE MARKET, BY TREATMENT TYPE
    92. PERIPHERAL ARTERY DISEASE MARKET, BY
    93. END USER
      1. MIDDLE EAST & AFRICA 95
    94. PERIPHERAL ARTERY
    95. DISEASE MARKET, BY TREATMENT TYPE
    96. PERIPHERAL ARTERY DISEASE MARKET, BY
    97. END USER
      1. MIDDLE EAST 99
    98. PERIPHERAL ARTERY DISEASE MARKET,
    99. BY TREATMENT TYPE
    100. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
      1. AFRICA 101
    101. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE
    102. PERIPHERAL ARTERY DISEASE MARKET, BY END USER
    103. COMPETITIVE LANDSCAPE:
    104. GLOBAL PERIPHERAL ARTERY DISEASE MARKET
      1. OVERVIEW 103
    105. COMPETITIVE ANALYSIS 103
    106. COMPANY PROFILES
      1. KONINKLIJKE
    107. PHILIPS NV 104
      1. COMPANY OVERVIEW 104
        1. FINANCIAL
    108. OVERVIEW 105
      1. PRODUCTS/SERVICES OFFERED 106
        1. KEY
    109. DEVELOPMENTS 106
      1. SWOT ANALYSIS 107
        1. KEY STRATEGIES
      2. B. BRAUN MELSUNGEN AG 108
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW 109
        3. PRODUCTS/SERVICES
    110. OFFERED 109
      1. KEY DEVELOPMENTS 110
        1. SWOT ANALYSIS
        2. KEY STRATEGIES 110
      2. COOK 111
    111. COMPANY OVERVIEW 111
      1. FINANCIAL OVERVIEW 111
    112. PRODUCTS/SERVICES OFFERED 111
      1. KEY DEVELOPMENTS 111
    113. SWOT ANALYSIS 112
      1. KEY STRATEGIES 112
      2. MEDTRONIC
        1. COMPANY OVERVIEW 113
        2. FINANCIAL OVERVIEW
        3. PRODUCTS/SERVICES OFFERED 115
        4. MEDTRONIC:
    114. KEY DEVELOPMENTS 115
      1. SWOT ANALYSIS 116
        1. KEY STRATEGIES
      2. BAYER AG 117
        1. COMPANY OVERVIEW 117
        2. FINANCIAL OVERVIEW 118
        3. PRODUCTS/SERVICES OFFERED 118
        4. KEY DEVELOPMENTS 119
        5. SWOT ANALYSIS 119
        6. KEY STRATEGIES 119
      3. BOSTON SCIENTIFIC CORPORATION 120
        1. COMPANY OVERVIEW 120
        2. FINANCIAL OVERVIEW 121
        3. PRODUCTS/SERVICES OFFERED 122
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS 123
        6. KEY STRATEGIES 123
      4. BECTON, DICKINSON AND COMPANY 124
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW 125
        3. PRODUCTS/SERVICES
    115. OFFERED 125
      1. KEY DEVELOPMENTS 126
        1. SWOT ANALYSIS
        2. KEY STRATEGIES 126
      2. TERUMO
    116. MEDICAL CORPORATION 127
      1. COMPANY OVERVIEW 127
    117. FINANCIAL OVERVIEW 128
      1. PRODUCTS OFFERED 128
    118. KEY DEVELOPMENTS 129
      1. SWOT ANALYSIS 129
        1. KEY STRATEGIES
      2. BIOTRONIK 130
        1. COMPANY OVERVIEW 130
        2. FINANCIAL OVERVIEW 130
        3. PRODUCTS OFFERED 130
        4. KEY DEVELOPMENTS 131
        5. SWOT ANALYSIS 132
    119. KEY STRATEGIES 132
      1. CARDINAL HEALTH 133
        1. COMPANY
    120. OVERVIEW 133
      1. FINANCIAL OVERVIEW 134
        1. PRODUCTS
    121. OFFERED 135
      1. KEY DEVELOPMENTS 135
        1. SWOT ANALYSIS
        2. KEY STRATEGIES 136
    122. APPENDIX
    123. REFERENCES 137
      1. RELATED REPORTS 137
    124. LIST OF TABLES
    125. DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 34
    126. GLOBAL PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION)
    127. BY REGION, 2023-2032 (USD MILLION) 36
    128. DISEASE MARKET, FOR ANGIOPLASTY STENTS (STENTING), BY REGION,
    129. (USD MILLION) 37
    130. CATHETERS, BY REGION, 2023-2032 (USD MILLION) 37
    131. ARTERY DISEASE MARKET, FOR PLAQUE MODIFICATION DEVICES (ATHERECTOMY), BY REGION,
    132. 2032 (USD MILLION) 38
    133. MARKET, FOR HEMODYNAMIC FLOW ALTERATION DEVICES, BY REGION,
    134. (USD MILLION) 38
    135. DRUGS, BY TYPE, 2023-2032 (USD MILLION) 40
    136. ARTERY DISEASE MARKET, FOR LIPID-LOWERING DRUGS, BY REGION, 2023-2032 (USD MILLION)
    137. LOWERING DRUGS, BY REGION,
    138. 2032 (USD MILLION) 41
    139. GLOBAL PERIPHERAL ARTERY DISEASE MARKET, FOR GLUCOSE REGULATING DRUGS, BY REGION,
    140. 2032 (USD MILLION) 41
    141. MARKET, FOR BLOOD CLOT PREVENTING DRUGS, BY REGION,
    142. 2032 (USD MILLION)
    143. (USD MILLION) 44
    144. HOSPITALS AND CLINICS, BY REGION, 2023-2032 (USD MILLION) 45
    145. GLOBAL PERIPHERAL ARTERY DISEASE MARKET FOR AMBULATORY SURGERY CENTERS, BY END USER,
    146. 2032 (USD MILLION) 45
    147. DISEASE MARKET, BY REGION, 2023-2032 (USD MILLION) 47
    148. PERIPHERAL ARTERY DISEASE MARKET, BY REGION, 2023-2032 (USD MILLION) 48
    149. (USD MILLION) 48
    150. FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 49
    151. ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 49
    152. AMERICAS: PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION)
    153. 2032 (USD MILLION) 51
    154. DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 51
    155. NORTH AMERICA: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032
    156. (USD MILLION) 52
    157. FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 52
    158. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 53
    159. MILLION) 53
    160. BY TYPE, 2023-2032 (USD MILLION) 54
    161. MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 54
    162. ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 55
    163. CANADA: PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
    164. TYPE, 2023-2032 (USD MILLION) 56
    165. MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 56
    166. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 57
    167. (USD MILLION) 57
    168. FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 58
    169. PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 58
    170. (USD MILLION) 59
    171. REGION, 2023-2032 (USD MILLION) 60
    172. DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 60
    173. EUROPE: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION)
    174. 2032 (USD MILLION) 61
    175. MARKET, BY END USER, 2023-2032 (USD MILLION) 62
    176. PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 63
    177. 2032 (USD MILLION) 64
    178. DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 64
    179. WESTERN EUROPE: PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032
    180. (USD MILLION) 65
    181. BY END USER, 2023-2032 (USD MILLION) 65
    182. ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 66
    183. GERMANY: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD
    184. MILLION) 66
    185. BY TYPE, 2023-2032 (USD MILLION) 67
    186. DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 67
    187. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 68
    188. 2032 (USD MILLION) 68
    189. MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 69
    190. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 69
    191. MILLION) 70
    192. BY TYPE, 2023-2032 (USD MILLION) 70
    193. MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 71
    194. ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 71
    195. ITALY: PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
    196. TYPE, 2023-2032 (USD MILLION) 72
    197. MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 73
    198. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 73
    199. (USD MILLION) 74
    200. DEVICES, BY TYPE, 2023-2032 (USD MILLION) 74
    201. ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 75
    202. SPAIN: PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION)
    203. BY TREATMENT TYPE, 2023-2032 (USD MILLION) 76
    204. EUROPE: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION)
    205. FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 77
    206. EUROPE: PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 77
    207. TYPE, 2023-2032 (USD MILLION) 78
    208. ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 78
    209. 2032 (USD MILLION) 79
    210. DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 79
    211. PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 81
    212. (USD MILLION) 81
    213. FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 82
    214. PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 82
    215. (USD MILLION) 83
    216. TREATMENT TYPE, 2023-2032 (USD MILLION) 83
    217. ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 84
    218. (USD MILLION) 84
    219. END USER, 2023-2032 (USD MILLION) 85
    220. DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 85
    221. JAPAN: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION)
    222. 2032 (USD MILLION) 86
    223. MARKET, BY END USER, 2023-2032 (USD MILLION) 87
    224. ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 87
    225. INDIA: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032 (USD
    226. MILLION) 88
    227. BY TYPE, 2023-2032 (USD MILLION) 88
    228. DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 89
    229. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 89
    230. 2032 (USD MILLION) 90
    231. MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 90
    232. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 91
    233. (USD MILLION) 91
    234. FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 92
    235. PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 92
    236. (USD MILLION) 93
    237. MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 93
    238. OF ASIA-PACIFIC: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032
    239. (USD MILLION) 94
    240. MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 94
    241. OF ASIA-PACIFIC: PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION)
    242. BY REGION, 2023-2032 (USD MILLION) 96
    243. PERIPHERAL ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 97
    244. DEVICES, BY TYPE, 2023-2032 (USD MILLION) 97
    245. AFRICA: PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION)
    246. BY END USER, 2023-2032 (USD MILLION) 98
    247. ARTERY DISEASE MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION) 99
    248. MIDDLE EAST: PERIPHERAL ARTERY DISEASE MARKET, FOR DEVICES, BY TYPE, 2023-2032
    249. (USD MILLION) 99
    250. FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 100
    251. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION) 100
    252. (USD MILLION) 101
    253. FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 101
    254. ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 102
    255. AFRICA: PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2032 (USD MILLION)
    256. B. BRAUN MELSUNGEN AG: PRODUCTS/SERVICES OFFERED 109
    257. BRAUN MELSUNGEN AG: KEY DEVELOPMENTS 110
    258. OFFERED 111
    259. MEDTRONIC: PRODUCTS/SERVICES OFFERED 115
    260. AG: KEY DEVELOPMENTS 119
    261. OFFERED 122
    262. OFFERED 125
    263. BIOTRONIK: PRODUCTS OFFERED 130
    264. CARDINAL HEALTH: KEY DEVELOPMENTS 135
    265. LIST OF FIGURES
    266. BOTTOM-UP AND TOP-DOWN APPROACHES 23
    267. OF THE GLOBAL PERIPHERAL ARTERY DISEASE MARKET 25
    268. FIVE FORCES ANALYSIS: GLOBAL PERIPHERAL ARTERY DISEASE MARKET 29
    269. VALUE CHAIN ANALYSIS OF THE GLOBAL PERIPHERAL ARTERY DISEASE MARKET 31
    270. TYPE, 2023-2032 (USD MILLION) 34
    271. MARKET FOR DEVICES, BY TYPE, 2023-2032 (USD MILLION) 35
    272. PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY TYPE, 2023-2032 (USD MILLION) 39
    273. 2032 (USD MILLION) 44
    274. MARKET SHARE, BY REGION, 2020 (%) 46
    275. DISEASE MARKET, BY REGION, 2023-2032 (USD MILLION) 46
    276. PERIPHERAL ARTERY DISEASE MARKET, BY REGION, 2023-2032 (USD MILLION) 47
    277. MILLION) 48
    278. BY REGION, 2023-2032 (USD MILLION) 50
    279. ARTERY DISEASE MARKET, BY REGION, 2023-2032 (USD MILLION) 51
    280. EUROPE: PERIPHERAL ARTERY DISEASE MARKET, BY REGION, 2023-2032 (USD MILLION) 59
    281. (USD MILLION) 60
    282. MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 62
    283. PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2032 (USD MILLION) 63
    284. (USD MILLION) 80
    285. BY COUNTRY, 2023-2032 (USD MILLION) 80
    286. PERIPHERAL ARTERY DISEASE MARKET, BY REGION, 2023-2032 (USD MILLION) 95
    287. 2032 (USD MILLION) 96
    288. COMPETITORS, 2020 (%) 103
    289. OVERVIEW SNAPSHOT 105
    290. SWOT ANALYSIS 112
    291. OVERVIEW SNAPSHOT 118
    292. BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 125
    293. TERUMO MEDICAL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 128
    294. TERUMO MEDICAL CORPORATION: SWOT ANALYSIS 129
    295. SWOT ANALYSIS 132

    Peripheral Artery Disease Market Segmentation

    Peripheral Artery Disease Treatment Type Outlook (USD Billion, 2018-2032)

    • Device
    • Catheters
    • Plaque Modification Devices
    • Hemodynamic Flow Alteration Devices
    • Others

    Peripheral Artery Disease Drugs Outlook (USD Billion, 2018-2032)

    • Lipid Lowering Drugs
    • Triple-H Therapy
    • Glucose Regulating Drugs
    • Blood Clot Preventing Drugs
    • Inotropes
    • Thrombolytic Agents
    • Anti-Inflammatory Agents

    Peripheral Artery Disease End User Outlook (USD Billion, 2018-2032)

    • Hospitals & Clinics
    • Ambulatory Surgical Clinics

    Peripheral Artery Disease Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

      • North America Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • North America Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs, Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • North America Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • US Outlook (USD Billion, 2018-2032)

      • US Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • US Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • US Peripheral Artery Disease by End User
        • Hospitals & Drugs
        • Ambulatory Surgical Clinics

      • CANADA Outlook (USD Billion, 2018-2032)

      • CANADA Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • CANADA Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • CANADA Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

    • Europe Outlook (USD Billion, 2018-2032)

      • Europe Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Europe Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Europe Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • Germany Outlook (USD Billion, 2018-2032)

      • Germany Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Germany Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Germany Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • France Outlook (USD Billion, 2018-2032)

      • France Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • France Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • France Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • UK Outlook (USD Billion, 2018-2032)

      • UK Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • UK Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • UK Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • ITALY Outlook (USD Billion, 2018-2032)

      • ITALY Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • ITALY Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • ITALY Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • SPAIN Outlook (USD Billion, 2018-2032)

      • Spain Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Spain Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Spain Peripheral Artery Disease by End User
        • Hospitals & Drugs
        • Ambulatory Surgical Clinics

      • Rest Of Europe Outlook (USD Billion, 2018-2032)

      • Rest Of Europe Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • REST OF EUROPE Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • REST OF EUROPE Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

    • Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Asia-Pacific Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Asia-Pacific Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Asia-Pacific Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • China Outlook (USD Billion, 2018-2032)

      • China Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • China Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • China Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • Japan Outlook (USD Billion, 2018-2032)

      • Japan Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Japan Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Japan Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • India Outlook (USD Billion, 2018-2032)

      • India Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • India Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • India Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • Australia Outlook (USD Billion, 2018-2032)

      • Australia Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Australia Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Australia Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Rest of Asia-Pacific Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Rest of Asia-Pacific Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Rest of Asia-Pacific Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

    • Rest of the World Outlook (USD Billion, 2018-2032)

      • Rest of the World Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Rest of the World Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Rest of the World Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • Middle East Outlook (USD Billion, 2018-2032)

      • Middle East Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Middle East Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Middle East Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • Africa Outlook (USD Billion, 2018-2032)

      • Africa Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Africa Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Africa Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics

      • Latin America Outlook (USD Billion, 2018-2032)

      • Latin America Peripheral Artery Disease by Treatment Type
        • Device
        • Catheters
        • Plaque Modification Devices,
        • Hemodynamic Flow Alteration Devices
        • Others
      • Latin America Peripheral Artery Disease by Drugs
        • Lipid Lowering Drugs
        • Triple-H Therapy
        • Glucose Regulating Drugs
        • Blood Clot Preventing Drugs,
        • Inotropes,
        • Thrombolytic Agents,
        • Anti-Inflammatory Agents
      • Latin America Peripheral Artery Disease by End User
        • Hospitals & Clinics
        • Ambulatory Surgical Clinics
    Peripheral Artery Disease Market Research Report - Forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027